BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/6/2020 2:37:44 AM | Browse: 650 | Download: 694
 |
Received |
|
2019-11-18 11:27 |
|
Peer-Review Started |
|
2019-11-08 14:08 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2019-12-12 00:32 |
|
Revised |
|
2019-12-31 15:07 |
|
Second Decision |
|
2020-01-06 09:23 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-01-08 17:14 |
|
Articles in Press |
|
2020-01-08 17:14 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-01-15 00:01 |
|
Typeset the Manuscript |
|
2020-02-04 00:56 |
|
Publish the Manuscript Online |
|
2020-02-06 02:37 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Case Report |
| Article Title |
Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with HER2 gene amplification: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qi Jiang, Mi-Xue Xie and Xiao-Chen Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Zhejiang Natural Science Foundation-Zhejiang Mathematical and Physical Medical Association |
SY19H310001 |
|
| Corresponding Author |
Xiao-Chen Zhang, MD, Associate Chief Physician, Chief Physician, Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou 310000, Zhejiang Province, China. zhangxiaochen@zju.edu.cn |
| Key Words |
Urothelial bladder carcinoma; Trastuzumab; Complete response; Next generation sequencing; HER2; Case report |
| Core Tip |
Urothelial bladder carcinoma (UBC) is the most common type of urinary system tumors. Approximately 25% of patients present de novo with metastatic disease affecting long-term survival. Although Cisplatin-based combination chemotherapy has become the standard first-line regimens for recurrent UBC patients, there are still no second- and third-line treatments for definite efficacy. HER2 gene amplification has been found in UBC patients, but there is not enough clinical evidence for incorporating trastuzumab for treatment of recurrent UBC. This case hinted that the recurrent UBC patient with HER2 gene amplification may benefit from targeted trastuzumab, and more cases in the future are needed to confirm our findings. |
| Publish Date |
2020-02-06 02:37 |
| Citation |
Jiang Q, Xie MX, Zhang XC. Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with HER2 gene amplification: A case report. World J Clin Cases 2020; 8(3): 594-599 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i3/594.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i3.594 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
